CollPlant Names Dr. Nadav Orr Vice President Research And Development

REHOVOT, Israel, September 8, 2014 /PRNewswire/ --

CollPlant (CLPT.TA), a developer and manufacturer of human collagen-based medical products has announced that Dr. Nadav Orr has been appointed Vice President of Research & Development, effective September 7, 2014.

Dr. Nadav Orr brings over 15 years of experience in research and development, including 9 years in the development of Biosurgery products. Before joining Collplant, Nadav served as an Associate Director, Research and Development at Omrix Biopharmaceuticals Ltd., a subsidiary of ETHICON Biosurgery, Johnson & Johnson. As part of his role at Omrix, Nadav led an international team in the development of hemostatic combination products and provided business support for production processes and products. Nadav holds a PhD in Immunology from the Weizmann Institute of Science, Israel.

"Nadav brings extensive expertise in the field of regenerative medicine, as well as management experience to CollPlant," says Yehiel Tal, CEO of CollPlant. "Nadav will have a major contribution to the development of our product pipeline and will be a great asset to CollPlant's management team. Under Nadav's direction, the CollPlant R&D team will be able to develop products at the fast pace required to compete in the Orthopedics and Wound Care markets, in which we operate."

About CollPlant:

CollPlant is a medical device firm established in 2004 to focus on advancing regenerative medicine through its cutting-edge technology designed to generate and process proprietary recombinant human collagen, among other patent-protected recombinant proteins. CollPlant is developing a broad spectrum of biomaterials for a wide variety of medical markets, including orthopedics, wound healing, and general surgery. CollPlant's business model consists of own development and manufacturing of medical devices and their commercialization and distribution together with leading third parties, alongside alliances with leading companies for joint development, manufacturing and marketing of additional

For more information about CollPlant, visit http://www.collplant.com

Contact:

Eran Rotem
Chief Financial Officer
Tel: +972-73-2325600/612
Email: [email protected] 

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.